Niagen Bioscience (NAGE) Stock Price, News & Analysis

Company Overview

Niagen Bioscience, Inc. is a life sciences company focused on products and technologies designed to support healthy aging and cellular health. The company’s principal technology is nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production and other biological processes.

The company develops and commercializes NIAGEN-branded NR ingredients for use in dietary supplements, functional foods and beverages, and other consumer health products. Its consumer portfolio includes Tru Niagen, a direct-to-consumer supplement brand, while its ingredient business supplies NIAGEN products to manufacturers and brand partners. The company also supports its products with scientific research, quality testing and intellectual-property licensing.

Niagen Bioscience was formerly known as ChromaDex Corporation and has been associated with research and commercialization efforts involving NAD+ biology and NR. Its products are marketed through online channels, retail distribution and commercial partners in the United States and international markets. The company is led by Chief Executive Officer Rob Fried.

Key Stats

• Today's Range: $2.67 to $2.79
• 50-Day Range: $2.68 to $3.53
• 52-Week Range: $2.61 to $7.95
• Volume: 864,774 shs
• Average Volume: 491,242 shs
• Market Capitalization: $213.45 million
• P/E Ratio: 14.89
• Dividend Yield: N/A
• Price Target: $10.33
• Consensus Rating: Buy

Niagen Bioscience Stock Analysis - MarketRank™

Niagen Bioscience scored higher than 46% of companies evaluated by MarketBeat, and ranked 113th out of 167 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Niagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Niagen Bioscience has a consensus price target of $10.33, representing about 285.6% upside from its current price of $2.68.

Amount of Analyst Coverage

Niagen Bioscience has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 7.69%

Earnings Growth

Earnings for Niagen Bioscience are expected to grow by 7.69% in the coming year, from $0.13 to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Niagen Bioscience is 14.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Niagen Bioscience is 14.89, which means that it is trading at a more expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 13.91.

Price to Book Value per Share Ratio

Niagen Bioscience has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.58% of the float of Niagen Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Niagen Bioscience has a short interest ratio ("days to cover") of 11.29, which indicates bearish sentiment.

Change versus previous month

Short interest in Niagen Bioscience has recently decreased by 3.84%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Niagen Bioscience does not currently pay a dividend.

Dividend Growth

Niagen Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 5 news articles for Niagen Bioscience this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for NAGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Niagen Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.00% of the stock of Niagen Bioscience is held by insiders.

Percentage Held by Institutions

15.41% of the stock of Niagen Bioscience is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: Personal Care Products
• Sub-Industry: Personal Care Products
• Current Symbol: NASDAQ:NAGE
• Previous Symbol: NASDAQ:NAGE
• CIK: 1386570
• Web: www.niagenbioscience.com
• Phone: (310) 388-6706
• Fax: 949-419-0294
• Employees: 117
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Niagen Bioscience: $10.33
• High Price Target: $11.00
• Low Price Target: $10.00
• Potential Upside/Downside: +285.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.18
• Trailing P/E Ratio: 14.89
• Forward P/E Ratio: 20.62
• P/E Growth: N/A
• Net Income: $17.38 million
• Net Margins: 12.39%
• Pretax Margin: 13.19%
• Return on Equity: 17.95%
• Return on Assets: 13.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.50
• Quick Ratio: 5.13

Sales & Book Value

• Annual Sales: $129.08 million
• Price / Sales: 1.65
• Cash Flow: $0.19 per share
• Price / Cash Flow: 13.76
• Book Value: $0.96 per share
• Price / Book: 2.79

Miscellaneous

• Outstanding Shares: 79,644,000
• Free Float: 71,680,000
• Market Cap: $213.45 million
• Optionable: N/A
• Beta: 2.02